When I spoke with my Strategic Tech Investor readers last week, I illustrated how one of our "Million-Dollar Tech Portfolio" stocks had soared 53% in just a little over two months. But Repligen Corp. (Nasdaq: RGEN) isn't the only big winner. In fact, six of our seven investments in the Million-Dollar Tech Portfolio are up […]Repligen Corp.
Article Index
The Tech Portfolio Built to Beat the Market
When I spoke with my Strategic Tech Investor readers last week, I illustrated how one of our "Million-Dollar Tech Portfolio" stocks had soared 53% in just a little over two months. But Repligen Corp. (Nasdaq: RGEN) isn't the only big winner. In fact, six of our seven investments in the Million-Dollar Tech Portfolio are up […]Two Divergent Northbound Stocks to Buy Right Now
I want to spend today talking to you about two stocks that we've repeatedly recommended to Private Briefing readers.
Both stocks made bullish headlines last week.
One of the stocks is a winner - a big winner, in fact. And the other has been a loser - so far.
But we're predicting it will be a big winner, too - a huge winner.
And last week's developments strengthened our case...
The Hottest Opportunities in Tech Right Now
Although I speak with Money Morning technology guru Michael Robinson almost every day - and share his comments and recommendations with you on a regular basis - it has been some time since we actually engaged in a full-fledged question-and-answer session for your benefit.
Today I'll share that Q&A with you.
In it, Michael - editor of our Nova-X Report and Radical Technology Profits advisories - details his outlook for stocks, outlines a risk-management strategy every investor should follow (especially now), and highlights the half-dozen tech stocks that will point you down the path to meaningful wealth.
Michael explains why today's seemingly outrageous valuations can be justified.
This Blockbuster Drug Has Room to Run
Editor's Note: We're sharing this Private Briefing with you because it contains a pick that's put Bill's readers up as much as 444% since he first recommended the stock...
Shares of blood-cancer drugmaker Pharmacyclics Inc. rocketed as much as 22% last Tuesday after the company exhilarated investors by forecasting that sales of its key drug would double this year.
We weren't surprised by this, of course.
But even more important was that Private Briefing readers weren't, either.
In a Private Briefing report back in early December, we said the Pharmacyclics blood-cancer drug Imbruvica (ibrutinib) was well on its way to becoming the blockbuster we predicted when we first recommended shares of the Sunnyvale, Calif.-based biotech back in April 2012.
That "call" was right on target.
Late last Monday, after the close of trading, Pharmacyclics said net-product revenue for Imbruvica for full-year 2014 would come in at $492 million. That would include sales of about $185 million in the fourth quarter alone - a hefty "sequential" (quarter-to-quarter) jump of 31%.
But here's the real stunner: For 2015, the company is looking at sales to more than double and reach $1 billion.
For those who want the actual numbers, that's a gain of 103%.
Imbruvica, you see, is shaping up to be the very blockbuster we told you it would be.
And that bodes well for Pharmacyclics shares.